Lundbeck: Switching Engines
Executive Summary
Lundbeck appears well-prepared for generic competition to its blockbuster antidepressant Cipramil. But the company still needs to broaden its pipeline and increase its profile in the US.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?